NeuroPace Announces Upcoming Oral Presentation of Data from the Post-Approval Study of the RNS System at the American Academy of Neurology 2025 Annual Meeting Being Held April 5th – 9th
NeuroPace (NPCE), a medical device company specializing in epilepsy treatment, announced that data from their RNS System Post-approval Study will be presented at the American Academy of Neurology (AAN) 2025 Annual Meeting. The presentation, titled 'Multicenter Post-approval Study of the RNS System in Focal Epilepsy,' will be delivered by Dr. Dawn Eliashiv, Professor of Neurology and Co-Director of UCLA Seizure Disorders Center. The session is scheduled for Monday, April 7th, at 5:06 PM PT during the Epilepsy Clinical Outcomes and Prognostication session at the conference being held in San Diego from April 5th to 9th.
NeuroPace (NPCE), un'azienda medica specializzata nel trattamento dell'epilessia, ha annunciato che i dati del loro Studio Post-approvazione del Sistema RNS saranno presentati al Congresso Annuale dell'Accademia Americana di Neurologia (AAN) 2025. La presentazione, intitolata 'Studio Multicentrico Post-approvazione del Sistema RNS nell'Epilessia Focale', sarà tenuta dal Dr. Dawn Eliashiv, Professore di Neurologia e Co-Direttore del Centro per i Disturbi Convulsivi presso UCLA. La sessione è programmata per lunedì 7 aprile, alle 17:06 PT durante la sessione sugli Esiti Clinici e Prognostico dell'Epilessia, nel congresso che si svolgerà a San Diego dal 5 al 9 aprile.
NeuroPace (NPCE), una empresa de dispositivos médicos especializada en el tratamiento de la epilepsia, anunció que los datos de su Estudio Post-aprobación del Sistema RNS serán presentados en el Congreso Anual de la Academia Americana de Neurología (AAN) 2025. La presentación, titulada 'Estudio Multicéntrico Post-aprobación del Sistema RNS en Epilepsia Focal,' será realizada por el Dr. Dawn Eliashiv, Profesor de Neurología y Co-Director del Centro de Trastornos Convulsivos de UCLA. La sesión está programada para el lunes 7 de abril, a las 5:06 PM PT, durante la sesión de Resultados Clínicos y Prognóstico de Epilepsia en la conferencia que se llevará a cabo en San Diego del 5 al 9 de abril.
NeuroPace (NPCE)는 간질 치료에 특화된 의료기기 회사로, 그들의 RNS 시스템 사후 승인을 위한 연구 데이터가 미국 신경학회 (AAN) 2025 연례 회의에서 발표될 것이라고 발표했습니다. 발표 제목은 '국소 간질에서 RNS 시스템의 다기관 사후 승인 연구'이며, Dr. Dawn Eliashiv UCLA 발작 장애 센터의 신경학 교수이자 공동 소장자가 발표합니다. 세션은 4월 7일 월요일 오후 5:06 PT에 샌디에고에서 4월 5일부터 9일까지 열리는 회의의 간질 임상 결과 및 예측 세션에서 진행될 예정입니다.
NeuroPace (NPCE), une entreprise de dispositifs médicaux spécialisée dans le traitement de l'épilepsie, a annoncé que les données de leur étude post-approbation du système RNS seront présentées lors de la Réunion Annuelle de l'Académie Américaine de Neurologie (AAN) 2025. La présentation, intitulée 'Étude Multicentrique Post-approbation du Système RNS dans l'Épilepsie Focale', sera faite par Dr. Dawn Eliashiv, Professeur de Neurologie et Co-Directeur du Centre des Troubles Convulsifs de l'UCLA. La session est prévue pour le lundi 7 avril à 17h06 PT pendant la session sur les Résultats Cliniques et la Prognostication de l'Épilepsie lors de la conférence qui se déroulera à San Diego du 5 au 9 avril.
NeuroPace (NPCE), ein Medizinprodukteunternehmen, das auf die Behandlung von Epilepsie spezialisiert ist, gab bekannt, dass die Daten ihrer RNS-System-Post-Approval-Studie auf dem Jahrestreffen der Amerikanischen Akademie für Neurologie (AAN) 2025 präsentiert werden. Die Präsentation mit dem Titel 'Multizentrische Post-Approval-Studie des RNS-Systems bei fokaler Epilepsie' wird von Dr. Dawn Eliashiv, Professorin für Neurologie und Co-Direktorin des UCLA Zentrums für Anfallserkrankungen, gehalten. Die Sitzung ist für Montag, den 7. April, um 17:06 Uhr PT im Rahmen der Sitzung zu klinischen Ergebnissen und Prognosen bei Epilepsie geplant, die während der Konferenz vom 5. bis 9. April in San Diego stattfindet.
- None.
- None.
MOUNTAIN VIEW, Calif., Feb. 03, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that an abstract featuring data from the Post-approval Study of the RNS System has been selected for an oral presentation at the upcoming American Academy of Neurology (AAN) 2025 Annual Meeting, which is being held April 5th – 9th in San Diego.
| Presentation Details: | |
| Title: | Multicenter Post-approval Study of the RNS System in Focal Epilepsy |
| Presenter: | Dr. Dawn Eliashiv, Professor of Neurology and Co-Director of the UCLA Seizure Disorders Center |
| Session: | S20: Epilepsy Clinical Outcomes and Prognostication |
| Presentation number: | 009 |
| Date and Time: | Monday, April 7th, at 5:06 PM PT |
About NeuroPace, Inc.
Based in Mountain View, Calif., NeuroPace is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is the first and only commercially available, brain-responsive platform that delivers personalized, real-time treatment at the seizure source. This platform can drive a better standard of care for patients living with drug-resistant epilepsy and has the potential to offer a more personalized solution and improved outcomes to the large population of patients suffering from other brain disorders.
Investor Contact:
Jeremy Feffer
Managing Director
LifeSci Advisors
jfeffer@lifesciadvisors.com
FAQ
When will NeuroPace (NPCE) present its RNS System study data at AAN 2025?
Who will present NeuroPace's (NPCE) RNS System data at AAN 2025?
What is the title of NPCE's presentation at AAN 2025?
Which session will feature NeuroPace's (NPCE) RNS System presentation at AAN 2025?
